VRTX — 8-K Filing

Item 5.02 — Departure / Election of Directors or Officers

Officer or director change — appointment, resignation, retirement, or termination, plus compensation arrangements.

Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficerOn March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval. A summary of the principal features of the Plan is set forth under Proposal No.

Item 5.07 — Submission of Matters to a Vote of Security Holders

Annual meeting / shareholder vote results.

The Annual Meeting was held on May 13, 2026. Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:Proposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider and Nancy Thornberry to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2027:ForAgainstAbstainNon-VotesSangeeta Bhatia221,280,1731,624,14193,32210,337,217Lloyd Carney213,048,5509,855,36993,71710,337,217Alan…